Autogenous Vaccines Market: By Strain Type (Bacterial Strain and Virus Strain), By End Users (Veterinary Clinics, Veterinary Hospitals, Veterinary Research Institutes, and Others), and Geography  

Autogenous Vaccines Market size was valued at USD 121.4 million in 2022 and is poised to grow at a CAGR of 5.8% from 2023-2029. Autogenous vaccines are established from the destruction and isolation of micro-organisms in diseased animals either individual animals or herds and are utilized to offer immunity to the same animals. These animal vaccines are primarily derivate from viral or bacterial strains. These demonstrate to be an advantageous option when there is no vaccine accessible for viral or bacterial infections, or in cases where present vaccines are not operative. Autogenous vaccines are permitted for use under the surveillance of a veterinarian or by government-assigned non-veterinarians. They are utilized to fight against numerous viral and bacterial infections in swine, bovine, avian, poultry, ruminant, fish, rabbit, horse, and other species. Initiatives taken by industry leaders in contacting directly to end customers will lead to better obtainability of products over the approaching years. The increase in rare communicable diseases in companion and livestock animals and the scarcity of suitable vaccines can lead to the growth of the autogenous vaccines market. Moreover, growing investment in veterinary biology research and development, and increasing funding in animal care are some primary factors that can boost the global autogenous vaccines market. Apart from these, an increase in drug resistance to anti-microbes can also accelerate the market in the future. However, some factors such as the absence of skilled professionals and stringent rules for approval of the product can restrain the growth of the market. The surge in animal care expenditure and research & development actions in the veterinary biologics industry can create an opportunity for the growth of the global autogenous vaccines market.

Autogenous Vaccines Market Key Developments:

• In October 2020, Ceva Santé Animale announced that it has increased its production capacity for bacterial autogenous vaccines (mainly, for pigs and poultry) at its French plant.
• In February 2021, INRAE and Ceva Santé Animale (Ceva) signed a first framework agreement meant for combining their association in animal health.